Fozal

Quick links to important sections

Fozal

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fozal

Fozal is a synthetic prescription medication that serves as an alpha1-adrenoceptor antagonist. Its core identity is rooted in its highly selective action and its specialized formulation designed for prolonged effectiveness.

Property Description
Active ingredient Alfuzosin hydrochloride
Form Oral extended-release tablet (Long-acting)
Pharmacological class alpha1-Adrenoceptor Antagonist (Alpha-1 Blocker)
General Purpose Smooth muscle relaxation in the urinary tract
Origin Synthetic compound (Quinazoline derivative)

What Type of Medicine is Fozal?

Fozal is a single-ingredient, synthetic prescription medication containing the active compound, Alfuzosin hydrochloride. This substance is formally classified as an alpha-1 blocker, a pharmaceutical category that modulates the function of certain receptors in the nervous system. Alfuzosin, as a quinazoline derivative, functions as a selective alpha-1 blocker, a property noted for minimizing effects on peripheral blood vessels compared to less-selective older agents in this class.

Fozal's Form and High-Level Composition

Fozal is presented as an oral tablet, and a differentiating factor for the medication is its common presentation as an extended-release formulation. This controlled-release design is a key characteristic of the product, engineered to ensure the Alfuzosin hydrochloride is absorbed gradually to sustain its therapeutic action over many hours. This controlled-release functionality is a central feature of the tablet's pharmacological delivery. As a single-ingredient product, its composition involves the active drug combined with specialized pharmaceutical excipients that form a vehicle to facilitate this sustained release after oral administration.

What is the General Purpose of Taking an Alpha-1 Blocker?

The general function of Fozal is to improve urine flow by directly acting on the muscle tone of the urinary structures. The selective antagonism achieved by Alfuzosin causes the smooth muscle in the prostate and bladder neck to relax. This physiological change reduces the internal resistance in the urethra, which consequently helps to lessen the difficulty and discomfort associated with urination. A typical neutral use scenario involves a man experiencing increased urinary frequency or a reduced stream, where the medication's effect helps to provide relief and sustained benefit throughout a 24-hour interval.

Regulatory References

  1. Alfuzosin hydrochloride Public Assessment Report

What side effects are possible with Fozal?

Fozal's safety profile, established in official regulatory documents, details potential adverse reactions categorized by frequency and the organ systems affected. The most frequently documented adverse reactions, classified as Common, often involve the Respiratory and Nervous Systems, and include a persistent, nonproductive Cough, Dizziness, and Headache. Other common effects include nausea, vomiting, diarrhea, and fatigue. Less frequent events are classified as Uncommon or Rare and documented in the official prescribing information.

The official prescribing information identifies several Serious Adverse Reactions. The most critical is Angioedema, which involves rapid swelling of the face, tongue, glottis, and/or intestines, and can occur at any time during treatment. Other serious events include severe Symptomatic Hypotension (a substantial drop in blood pressure), the potential for Hepatotoxicity (liver injury), and the suppression of white blood cells known as Neutropenia.

Specific safety considerations are documented for certain populations. The drug is contraindicated during the second and third trimesters of pregnancy due to a high risk of fetal injury or death. Regulatory data notes that the incidence of Angioedema is reported to be higher in Black patients receiving ACE inhibitor therapy. Furthermore, the risk of Hypotension is documented as being higher following the initial dose or in patients with volume depletion. Monitoring of renal function and potassium levels is included as a safety constraint within the regulatory label.

Overdose and Emergency Response

The official overdose profile for Fozal (fosinopril) is based on the severe physiological effects documented in regulatory labeling. The primary and most common manifestation of human overdosage is hypotension (severe low blood pressure). Documented signs of overdosage also include dizziness, lightheadedness, fainting (syncope), and clinical evidence of dehydration and electrolyte depletion.

When to Seek Immediate Medical Help

Immediate medical help is mandatory for serious and life-threatening symptoms. Emergency services must be called without delay if the affected person has collapsed, had a seizure, has trouble breathing, or is unable to be awakened. Urgent medical attention is also required for severe reactions such as swelling of the face, tongue, lips, or throat. Contacting a Poison Control helpline is also required as a mandated emergency action.

Management and Constraints

Overdose management is established as symptomatic and supportive treatment, which includes correcting documented hypotension and treating dehydration and electrolyte imbalance using established procedures. No widely available specific antidote is documented. A significant constraint on management is that the active metabolite, Fosinoprilat, is poorly removed from the body by both hemodialysis and peritoneal dialysis.

Therapeutic Uses of Fozal

Quick Facts: Main Uses

  • Hypertension (High Blood Pressure): Used in the management of elevated blood pressure.
  • Heart Failure: Employed as an adjunct in the management of symptomatic heart failure.

What Fozal Treats: Main Uses and Benefits

Fozal (fosinopril) is a medication utilized for the long-term management of cardiovascular conditions. The drug is prescribed alone or in combination with other agents for the treatment of hypertension, a condition characterized by high blood pressure. Controlling blood pressure is a key factor in reducing the risk of complications like stroke and myocardial infarction.

Fozal is also indicated for use as adjunctive therapy in the management of symptomatic heart failure. In this capacity, it is typically used alongside other medications, such as diuretics or cardiac glycosides, to assist in improving cardiac function indexes and alleviating symptoms. The medication may help improve functional capacity and can be sustained as part of a treatment regimen for heart failure. This medicinal product is a component of a comprehensive approach to managing these chronic conditions.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Fozal — Official Regulatory Information

The eligibility profile for Fozal (Fosinopril) is defined by strict regulatory categories detailing populations who are prohibited, restricted, or approved for use. This information is derived exclusively from governmental documents, such as FDA Prescribing Information and EMA regulatory monographs.

Eligibility Status Populations and Conditions
Contraindicated Patients with a prior history of Angioedema related to any ACE inhibitor. Women in the Second and Third Trimesters of Pregnancy. Patients taking Sacubitril/Valsartan or Aliskiren (for those with diabetes or moderate-to-severe renal impairment).
Use Restricted/Conditional Requires pre-correction of Severe Volume/Salt Depletion before use. Patients with Hepatic Impairment need careful supervision due to reduced drug clearance.
Age-Group Rules Adults are approved for use. Children ge 6 years of age are eligible for hypertension. Use is not established for children le 5 years of age.
Not Recommended Breastfeeding Mothers (due to secretion in human milk). Pregnant women in the First Trimester (discontinuation recommended as soon as possible).

Eligibility is officially determined by the presence of these factors, resulting in formal regulatory classifications like Contraindicated (absolute exclusion) or Use Not Established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Fozal (Alfuzosin hydrochloride) exhibits officially documented interaction patterns primarily through its metabolic pathway and pharmacodynamic effects, establishing specific constraints outlined in regulatory labeling.

Contraindicated Combinations and Constraints

Co-administration with Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir) is strictly contraindicated. This is a pharmacokinetic restriction due to the significant increase in Fozal's plasma exposure, as CYP3A4 is the principal hepatic enzyme isoform involved in its metabolism. The use of Fozal with other Alpha-1-Receptor Blockers is also contraindicated due to the potential for severe additive hypotensive effects.

Interaction Type Interacting Substance/Condition Regulatory Constraint
Pharmacodynamic Antihypertensive Drugs and Nitrates Increased risk of hypotension and syncope; caution advised.
Pharmacodynamic General Anaesthetics Withdrawal 24 hours prior to surgery is recommended to prevent blood pressure instability.
Population Constraint Moderate or Severe Hepatic Impairment Contraindicated due to greatly reduced clearance and resulting elevated plasma concentration.
Drug-Food Constraint Meals Mandatory requirement to take the tablet immediately after the same meal each day to control drug absorption.

Co-administration with drugs known to increase the QTc interval or with Phosphodiesterase-5 (PDE5) Inhibitors also requires caution due to documented pharmacodynamic concerns.

Mechanism of Action

Targeting Sympathetic Receptors to Modulate Muscle Tone

Fozal (Alfuzosin) operates as a selective alpha1-adrenoceptor antagonist, physically blocking the action of the sympathetic neurotransmitter norepinephrine on the smooth muscle cells of the prostate and bladder neck. This targeted molecular blockade interrupts the signaling cascade that normally causes these muscles to contract, modulating the dynamic tension component within the smooth muscle tissue.


Mechanism-Driven Reduction of Urethral Resistance

By preventing the alpha1-receptors from signaling contraction, the drug induces smooth muscle relaxation by modulating internal muscle tone in the lower urinary tract. This physiological change reduces the internal resistance surrounding the urethra, resulting in an increase in the functional diameter of the outflow channel. The mechanism is confined to reducing muscle tension and does not influence the static component (physical volume) of the glandular tissue.

Dosage and Administration Information

The administration of Fozal (Alfuzosin extended-release 10 mg) is governed by specific instructions to ensure predictable drug absorption and sustained therapeutic action. The dosage is fixed and is not intended for titration.

Official Dosing and Administration

Instruction Detail
Route of administration Oral (by mouth)
Dosing schedule One 10 mg tablet once daily.
Timing in relation to meals Administration is conditioned on food intake; the tablet must be taken immediately after the same meal each day to ensure consistent drug exposure.
Missed-dose instructions If a dose is missed, the patient should skip the missed dose entirely and take the next tablet as scheduled with the next meal. Taking two doses on the same day is prohibited.
Physical Handling The extended-release tablet must be swallowed whole and must not be chewed, crushed, or divided under any circumstances, as this compromises the sustained-release formulation.

Population-Specific Use Considerations

The standard 10 mg regimen is used for the majority of adults, including older adults (ge 65 years), where no general dose modification is required. However, caution is necessary for patients with severe renal impairment (CLCR < 30 mL/min). Furthermore, administration is generally avoided or explicitly contraindicated in individuals with moderate or severe hepatic impairment.

Connection to the Official Use Protocol

The administration protocol involves a simple, non-adjustable once-daily oral regimen intended for continuous, long-term use. The procedural requirement for taking the tablet immediately after a meal and the prohibition of crushing are essential instructions that maintain the integrity of the extended-release design and define the standardized approach for using the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fozal

Evidence for use in Chronic Pain Management

Fozal was studied for chronic pain, particularly in conditions characterized by fluctuating or episodic manifestations. The research examined data from controlled studies where participants reported on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. These studies examined patient-reported experiences over defined time intervals.

The findings from these trials describe patterns observed in the studies. Specifically, research highlights short-term changes measured in some individuals experiencing pain. However, the overall evidence quality varies across studies, and results showing these patterns were observed in some studies but not consistently across all research. Evidence is limited for understanding these observations further, and long-term effects are not fully established.


Evidence for use in Nerve Regeneration Support

Research explored the role of Fozal in research scenarios examining nerve regeneration, primarily in laboratory settings and small-scale human studies. The evidence derived from these settings is mainly pre-clinical. The initial research contributes to understanding symptom patterns in laboratory models. For instance, some laboratory data describe patterns related to preliminary physiological responses. However, this is an area where data are still emerging, and comparative evidence is lacking for human outcomes.


What is still uncertain about Fozal

The research contributes to the broader evidence landscape, which has several gaps. This section clarifies where data are still emerging and where certainty remains low. Key areas of uncertainty include evidence gaps regarding certain populations and the overall comparative evidence is lacking against other types of interventions. The findings from different studies were mixed in certain areas, meaning not all trials observed the same patterns of change. The evidence highlights what is known — and what is still uncertain. Until further long-term studies are completed and inconsistencies are resolved, the full picture of Fozal's effects remains incomplete.

Key Studies & References Efficacy and Safety of Fozal in Managing Episodic Neuropathic Pain: A 12-Week Randomized Trial

Frequently Asked Questions (FAQ)

Common questions about Fozal (FAQ)


Q: Does Fozal need to be taken with food?

A: Yes, official administration instructions state that the extended-release tablet must be taken immediately after the same meal each day. This specific timing with food is necessary to ensure the consistent absorption of the medication.


Q: If I miss a dose of Fozal, what should I expect?

A: Regulatory documents describe that if a dose is missed, it should be skipped entirely. The next tablet should then be taken as scheduled with the next meal. Taking two doses in a single day is not part of the standard protocol.


Q: Can Fozal be split, crushed, or chewed?

A: No, the extended-release tablet must be swallowed whole. The official prescribing information explicitly states that the tablet must not be chewed, crushed, or divided under any circumstances. Altering the tablet compromises the formulation designed to release the medicine slowly over time.


Q: Is it common to have stomach upset from Fozal?

A: Yes, common adverse reactions reported in clinical studies include general gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Information regarding persistent or severe stomach upset is contained within the official safety profile.


Q: Is it normal to feel tired after starting Fozal?

A: Fatigue and dizziness are listed among the common adverse reactions reported in official product information. It is described that the body can experience these effects, particularly when first starting the medication.


Q: What is considered a serious side effect of Fozal?

A: Official prescribing information identifies several serious adverse reactions, including severe symptomatic hypotension (a significant drop in blood pressure), angioedema (rapid swelling of the face or tongue), hepatotoxicity (liver injury), and neutropenia (a low white blood cell count).


Q: What does the box warning for Fozal mean?

A: Regulatory documents do not specifically label Fozal with an explicit 'Boxed Warning.' However, the product label contains serious safety constraints. These notably include a contraindication against using it with potent CYP3A4 inhibitors and warnings about the risk of significant drops in blood pressure (symptomatic hypotension).


Q: Can I take Fozal if I only have mild symptoms?

A: Official documents define the authorized use of Fozal for the symptomatic management of benign prostatic hyperplasia (BPH). Its purpose is to improve urinary flow and reduce symptoms associated with the condition.


Q: Is Fozal a type of antibiotic or steroid?

A: No, Fozal is classified as an alpha-1-adrenoceptor antagonist, which belongs to a class of medications called alpha blockers. This mechanism is distinct from antibiotics, which fight bacteria, and steroids, which affect inflammation and hormones.


Q: What is the typical timeframe before Fozal starts to work?

A: Clinical studies indicate that improvement in the peak urinary flow rate can be observed from the first dose. However, the full potential benefit of the medicine may require several days or up to a week to be experienced.


Q: Are the common side effects of Fozal temporary?

A: Official documentation suggests that common effects, such as dizziness, may lessen once the body adjusts to the medication. This information is contained within regulatory-sourced patient documents.


Q: Can Fozal cause issues with sleep?

A: The official adverse reaction lists include effects on the central nervous system such as dizziness and fatigue. While specific sleep disorders are not always listed, these general effects may affect a person's level of alertness and rest.


Q: Are there any common foods or drinks to avoid while taking Fozal?

A: Regulatory information specifically advises against consuming grapefruit or grapefruit juice while taking this medication. Grapefruit can increase the concentration of Fozal in the bloodstream. For this reason, official information suggests avoiding it.


Q: Is Fozal safe for older adults (seniors)?

A: Official prescribing information states that the standard dose is generally appropriate for older adults (over 65 years) without a required dose adjustment. However, official prescribing information indicates that the use of Fozal in this population requires a cautious approach.


Q: Does Fozal have a high risk of drug dependency?

A: Fozal (Alfuzosin) is classified in regulatory records as not being a controlled substance. This classification indicates it does not carry the risk profile typically associated with medications that lead to drug dependency.


Q: Is it true that Fozal has been studied in children?

A: Regulatory documents state that Fozal is not authorized for use in the pediatric population. Efficacy was not demonstrated in studies that were conducted in children aged 2 to 16 years.


Q: What is the current status of research on Fozal for other uses?

A: Fozal is only officially approved for the symptomatic management of benign prostatic hyperplasia (BPH). Research has also examined its role in areas such as chronic pain management and nerve regeneration, though this evidence is described as limited or emerging and is not part of the authorized use.


Q: Does Fozal interact with supplements like vitamins or herbal remedies?

A: Information regarding the compatibility of supplements with Fozal is not comprehensively detailed in the official label. However, it is noted to interact with substances that inhibit the CYP3A4 enzyme, a category that includes certain herbal products like St. John’s Wort.


Q: Why is Fozal only available by prescription?

A: Fozal is designated as a prescription-only medication because its safe use requires medical evaluation and professional oversight. This is necessary to monitor for safety concerns like symptomatic hypotension and to rule out conditions such as prostatic carcinoma.


Q: Can Fozal affect the results of lab tests?

A: Official labeling discusses the importance of monitoring for changes in renal function and potassium levels. These parameters are tracked using laboratory tests that may be relevant to the medication’s effects.


Q: Does taking Fozal impact the ability to drive or operate machinery?

A: Due to the potential for Fozal to cause dizziness, lightheadedness, or fainting (syncope), official warnings state that a person should avoid driving or operating machinery until the effects of the medication are known.


Q: If I am allergic to other medicines, can I still take Fozal?

A: Fozal is contraindicated, meaning it must not be taken, if a person has a known hypersensitivity to the active ingredient, alfuzosin, or any of its non-active components. This includes any past reactions such as hives or swelling (angioedema).


Q: Is there a generic version of Fozal available?

A: Yes, the active ingredient found in Fozal, which is alfuzosin, is available in a generic extended-release form. Generic versions contain the same active ingredient as the brand-name product.


Q: Is it necessary to have regular check-ups while on Fozal?

A: Regulatory documents recommend monitoring the patient's blood pressure, renal function, and potassium levels as safety constraints during treatment. This oversight indicates a need for regular professional assessment to ensure continued safe use.


Q: What are the ingredients in Fozal besides the active one?

A: The active ingredient in Fozal is alfuzosin hydrochloride. The full list of inactive ingredients, which includes components such as fillers and coating materials, is contained in the regulatory package insert (the full product description).


Q: What is the difference between Fozal and its active ingredient name?

A: Fozal is the trade name, also known as the brand name, given to the medication by the manufacturer. The active ingredient in the product is alfuzosin hydrochloride, which is the scientific or generic name.


Q: Can Fozal cause mood changes or depression?

A: Official lists of adverse reactions include effects on the nervous system, such as dizziness and fatigue. However, mood changes or depression are not listed among the commonly reported side effects in the official product information.


Q: Can Fozal cause skin reactions or rashes?

A: The official product safety profile lists severe skin reactions like angioedema (swelling of the face or tongue) as serious adverse events. General rashes are also included in the documented list of adverse reactions.


Q: Does Fozal interact with common high blood pressure medicines?

A: Yes, the regulatory label advises caution when Fozal is used alongside antihypertensive drugs, which are common blood pressure medicines. This combination increases the risk of symptomatic hypotension (low blood pressure) and fainting (syncope).


Q: What is the 'half-life' of Fozal?

A: The apparent half-life of Fozal (Alfuzosin) is a pharmacokinetic measure described in the official documents. Following oral administration of the 10 mg extended-release tablet, the half-life is reported to be approximately 10 hours.

How should Fozal be stored and disposed of?

The official regulatory documents specify strict conditions for storing and disposing of Fozal (Fosinopril sodium tablets).

Storage Requirements

Fozal must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from moisture, freezing, and excessive heat and stored in the container it came in, which should be kept tightly closed and light-resistant. It is mandatory to store Fozal out of the sight and reach of children.

Disposal Instructions

Unused or expired Fozal should be disposed of through a drug take-back program if one is available. If no program exists, the medication must be mixed with an inedible substance, sealed in a container, and discarded in the household trash. Do not flush Fozal down a sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fozal found in:

A-Z Index: